Cargando…

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

Patients with multiple myeloma (MM) accumulate adverse copy number aberrations (CNAs), gains of 1q21, and 17p deletions during disease progression. A subset of these patients develops heightened 1q12 pericentromeric instability and jumping translocations of 1q12 (JT1q12), evidenced by increased copy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawyer, Jeffrey R., Tian, Erming, Walker, Brian A., Wardell, Christopher, Lukacs, Janet L., Sammartino, Gael, Bailey, Clyde, Schinke, Carolina D., Thanendrarajan, Sharmilan, Davies, Faith E., Morgan, Gareth J., Barlogie, Bart, Zangari, Maurizio, van Rhee, Frits
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689064/ https://www.ncbi.nlm.nih.gov/pubmed/31399558 http://dx.doi.org/10.1038/s41408-019-0226-4

Ejemplares similares

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
por: Schinke, Carolina, et al.
Publicado: (2019)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
por: Al Hadidi, Samer, et al.
Publicado: (2022)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
por: Ling, Wen, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
por: Larsen, Kristin, et al.
Publicado: (2022)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
por: Schinke, Carolina, et al.
Publicado: (2020)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

An Evaluation of Gene Set Analysis for Biomarker Discovery with Applications to Myeloma Research
por: Qu, Pingping, et al.
Publicado: (2017)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant
por: Mathur, Pankaj, et al.
Publicado: (2017)

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
por: Rasche, L., et al.
Publicado: (2017)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling
por: Weinhold, N, et al.
Publicado: (2015)

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols
por: Singh, Zeba N, et al.
Publicado: (2015)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma
por: Mathur, Pankaj, et al.
Publicado: (2020)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma
por: Mathur, Pankaj, et al.
Publicado: (2017)

Necrotizing Enterocolitis in a Patient With Newly Diagnosed Multiple Myeloma and Hyperviscosity Syndrome: A Case Report
por: Patel, Tanvi H, et al.
Publicado: (2023)

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
por: Chavan, S S, et al.
Publicado: (2017)

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
por: Papanikolaou, Xenofon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tnumfsd6k1io9kj2v2rqt2pokb